Our RESETTM clinical trials with CABA-201 (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/15/24 | 8-K | Current report filing |
|
   |
29 |
| 04/23/24 | ARS | Annual report to security holders |
|
160 | |
| 04/23/24 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/23/24 | DEF 14A | Definitive proxy statements |
|
46 | |
| 03/21/24 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |
|
210 | |
| 03/21/24 | S-8 | Initial registration statement for securities to be offered to employees pursuant to employee benefit plans |
|
6 | |
| 03/21/24 | 10-K | Annual report pursuant to Section 13 and 15(d) |
|
|
182 |
| 03/21/24 | 8-K | Current report filing |
|
|
9 |
| 03/20/24 | 8-K | Current report filing |
|
|
7 |
| 03/04/24 | 4 | Statement of changes in beneficial ownership of securities |
|
1 |
